Key facts
- N.B.Medical’s last known valuation is $39.7M (Mar 2026).
- It has raised $26.2M; the latest was Grant ($3.2M) in Mar 2026.
- Notable investors include Mitsubishi UFJ Capital, Mizuho Capital, ANRI, Beyond Next Ventures, AIST Solutions — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for N.B.Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for N.B.Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About N.B.Medical
Developer of neurovascular medical devices and in silico regulatory technologies designed to enable precise, efficient, and accelerated medical device development. The company integrates real world medical device R&D with a regulation integrated computational modeling and simulation (CMS) platform and AI driven digital twin technologies, embedding CMS into each stage of the development process and linking AI enabled regulatory documentation with physical device development and testing, enabling medical device manufacturers to streamline regulatory workflows, improve development accuracy and bring innovative neurovascular devices to market more efficiently.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2021
- Employees
- 10
- Website
- nbmed-inc.com/
- Ownership
- Privately Held (backing)
N.B.Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in N.B.Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on N.B.Medical in its N-PORT filings yet. We sweep new filings monthly.